COGT
Cogent Biosciences Inc.
$33.94
+$1.27(+3.89%)
44
Overall
40
Value
50
Tech
42
Quality
Market Cap
$4.62B
Volume
2.78M
52W Range
$4.80 - $43.73
Target Price
$54.25
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | $9.7M | -- | $7.9M | $2.5M | $2.6M | $950.0K | -- | -- | ||
| Total Revenue | $9.7M | -- | $7.9M | $2.5M | $2.6M | $950.0K | -- | -- | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | -- | -- | $-46.9M | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | -- | -- | $54.8M | $2.5M | $2.6M | $950.0K | -- | -- | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $45.7M | $54.7M | $43.2M | $75.6M | $147.8M | $208.1M | $275.9M | $333.4M | ||
| Research & Development | $38.3M | $43.7M | $25.7M | $55.9M | $121.6M | $173.8M | $232.7M | $269.8M | ||
| Research Expense | $38.3M | $43.7M | $25.7M | $55.9M | $121.6M | $173.8M | $232.7M | $269.8M | ||
| Selling, General & Administrative | $7.5M | $11.0M | $17.4M | $19.6M | $26.2M | $34.4M | $43.3M | $63.6M | ||
| General & Administrative Expenses | $7.5M | $11.0M | $17.4M | $19.6M | $26.2M | $34.4M | $43.3M | $63.6M | ||
| Salaries & Wages | $-3.1M | $-3.2M | -- | -- | $18.4M | -- | -- | -- | ||
| Depreciation & Amortization | $-1.3M | $-1.3M | $700.0K | $100.0K | $800.0K | $2.3M | $2.5M | -- | ||
| Depreciation & Amortization | $-1.3M | $-1.3M | $700.0K | $100.0K | $800.0K | -- | -- | -- | ||
| Other Operating Expenses | -- | $-1.8M | $2.2M | $2.4M | $4.1M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-45.7M | $-54.7M | $-82.2M | $-75.6M | $-147.8M | $-208.1M | $-275.9M | $-333.4M | ||
| EBITDA | $-33.5M | $-30.6M | $-34.6M | $-73.6M | $-134.4M | $-188.8M | $-251.5M | $-320.7M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | $3.1M | ||
| Intinc | $1.2M | $267.0K | $144.0K | $467.0K | $4.0M | $13.1M | $18.1M | $14.7M | ||
| Net Non-Operating Interest Income/Expense | $1.2M | $267.0K | $144.0K | $467.0K | $4.0M | $13.1M | $18.1M | $11.6M | ||
| Other Income/Expense | $-10.1M | $-22.6M | $-7.2M | $-2.8M | $3.6M | $-943.0K | $-2.0M | $7.2M | ||
| Other Special Charges | $10.1M | $22.5M | $-246.0K | $2.8M | $2.2M | $943.0K | $2.0M | $-7.2M | ||
| SPECIAL ITEMS | ||||||||||
| Restructring And Mn A Income | -- | -- | $4.2M | -- | -- | -- | -- | -- | ||
| Special Income Charges | -- | -- | $-4.2M | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-34.5M | $-31.8M | $-35.3M | $-75.6M | $-140.2M | $-192.4M | $-255.9M | $-325.9M | ||
| Pre-Tax Income | $-34.5M | $-31.8M | $19.0M | $-72.3M | $-141.6M | $-194.1M | $-255.9M | $-328.9M | ||
| NET INCOME | ||||||||||
| Net Income | $-34.5M | $-31.8M | $-74.8M | $-72.3M | $-140.2M | $-192.4M | $-255.9M | $-328.9M | ||
| Net Income (Continuing Operations) | $-34.5M | $-31.8M | $-74.8M | $-72.3M | $-140.2M | $-192.4M | $-255.9M | $-328.9M | ||
| Net Income (Discontinued Operations) | $-34.5M | $-31.8M | $-74.8M | $-72.3M | $-140.2M | $-192.4M | $-255.9M | $-328.9M | ||
| Net Income (Common Stockholders) | $-34.5M | $-31.8M | $-179.2M | $-72.3M | $-140.2M | $-192.4M | $-255.9M | $-328.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-325.6M | ||
| TOTALS | ||||||||||
| Total Expenses | $45.7M | $54.7M | $-3.8M | $75.6M | $147.8M | $208.1M | $275.9M | $333.4M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $24.9M | $7.6M | $11.1M | $38.7M | $58.7M | $79.7M | $103.9M | $128.9M | ||
| Average Shares Outstanding (Diluted) | $30.0B | $7.6M | $11.1M | -- | $58.7M | $79.7M | $103.9M | $128.9M | ||
| Shares Outstanding | $30.1M | $30.6M | $37.2M | $45.8M | $69.9M | $170.9M | $113.9M | $162.3M | ||
| Basic EPS | $-0.29 | $0.07 | $-16.17 | $-1.87 | $-2.39 | $-2.42 | $-1.94 | $-2.16 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-16.17 | $-1.87 | $-2.39 | $-2.42 | $-1.94 | $-2.16 | ||
| Diluted EPS | $-1.39 | $-4.18 | $-16.17 | $-1.87 | $-2.39 | $-2.42 | $-1.94 | $-2.16 | ||
| Diluted EPS (Continuing Operations) | -- | $-4.18 | -- | -- | $-2.39 | $-2.42 | $-1.94 | $-2.16 | ||
| OTHER METRICS | ||||||||||
| Accretion On Preferred Stock | $16.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | -- | -- | $104.4M | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | $78.0K | $7.5M | -- | -- | -- | -- | -- | ||
| Other Gand A | $7.5M | $11.0M | $17.4M | $19.6M | $26.2M | $34.4M | $43.3M | $63.6M | ||
| Other Taxes | $-200.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $16.0K | -- | $104.4M | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $7.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | $4.2M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | COGT | $33.94 | +3.9% | 2.78M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |